Sunshine Biopharma (SBFM) Operating Expenses (2010 - 2026)

Sunshine Biopharma (SBFM) has reported Operating Expenses for 16 consecutive years, with $4.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 26.52% year-over-year to $4.8 million; the trailing twelve-month figure through Jun 2026 stood at $20.6 million (down 8.9% YoY), and the FY2025 full-year result was $23.1 million, up 11.88% from the prior year.
• Operating Expenses grew to $4.8 million in Q2 2026 per SBFM's latest filing, from $4.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.9 million in Q4 2022 and bottomed at $819650.0 in Q2 2022.
• Historically, Operating Expenses has averaged $5.5 million across 5 years, with a median of $4.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 6161.52% in 2022, then sank 78.74% in 2023.
• Over 5 years, Operating Expenses stood at $24.9 million in 2022, then tumbled by 78.74% to $5.3 million in 2023, then rose by 16.59% to $6.2 million in 2024, then advanced by 2.89% to $6.4 million in 2025, then decreased by 24.21% to $4.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $4.8 million, $4.5 million, and $6.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.